Venetoclax

Generic Name
Venetoclax
Brand Names
Venclexta, Venclyxto
Drug Type
Small Molecule
Chemical Formula
C45H50ClN7O7S
CAS Number
1257044-40-8
Unique Ingredient Identifier
N54AIC43PW
Background

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...

Indication

本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。

Associated Conditions
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Associated Therapies
-
Clinical Trials
Related News

Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

First Posted Date
2023-11-29
Last Posted Date
2024-08-23
Lead Sponsor
Centre Leon Berard
Target Recruit Count
35
Registration Number
NCT06150040
Locations
🇫🇷

Centre Léon Bérard, Lyon, France

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Phase 1
Not yet recruiting
Conditions
Myeloid Malignancy
Acute Myeloid Leukemia
Interventions
Drug: Venetoclax
Drug: Decitabine
First Posted Date
2023-11-13
Last Posted Date
2024-11-15
Lead Sponsor
Benjamin Tomlinson
Target Recruit Count
20
Registration Number
NCT06129734
Locations
🇺🇸

University Hospitals Seidman Cancer, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Phase 2
Not yet recruiting
Conditions
Multiple Myeloma in Relapse
Multiple Myeloma, Refractory
Interventions
Drug: Venetoclax
First Posted Date
2023-11-02
Last Posted Date
2024-01-24
Lead Sponsor
Oncotherapeutics
Target Recruit Count
39
Registration Number
NCT06115135

Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS

First Posted Date
2023-10-31
Last Posted Date
2023-10-31
Lead Sponsor
Anhui Provincial Hospital
Target Recruit Count
14
Registration Number
NCT06109064
Locations
🇨🇳

The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China

Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML

First Posted Date
2023-10-27
Last Posted Date
2023-10-30
Lead Sponsor
Anhui Provincial Hospital
Target Recruit Count
20
Registration Number
NCT06105658
Locations
🇨🇳

The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

First Posted Date
2023-10-17
Last Posted Date
2024-03-07
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT06085638

CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

First Posted Date
2023-10-11
Last Posted Date
2024-04-22
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
20
Registration Number
NCT06078306
Locations
🇨🇳

Xiaowen Tang, Suzhou, Jiangsu, China

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

First Posted Date
2023-10-10
Last Posted Date
2024-12-13
Lead Sponsor
BeiGene
Target Recruit Count
640
Registration Number
NCT06073821
Locations
🇺🇸

John Muir Medical Center, Concord, California, United States

🇺🇸

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla, California, United States

🇺🇸

UCLA Department of Medicine Hematologyoncology, Los Angeles, California, United States

and more 228 locations

A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants

Phase 1
Withdrawn
Conditions
Healthy Volunteers
Interventions
Drug: Venetoclax
First Posted Date
2023-10-06
Last Posted Date
2024-06-21
Lead Sponsor
AbbVie
Registration Number
NCT06070948
Locations
🇺🇸

Acpru /Id# 259897, Grayslake, Illinois, United States

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

First Posted Date
2023-09-18
Last Posted Date
2024-12-02
Lead Sponsor
Mayo Clinic
Target Recruit Count
100
Registration Number
NCT06042725
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy